ALBUQUERQUE, N.M., Oct. 28, 2024
ALBUQUERQUE, N.M., Oct. 28, 2024 /PRNewswire/ -- T-Neuro Pharma, a leading biotechnology company dedicated to developing innovative therapies for neurodegenerative diseases, announced today that it will present new research on its T-Track blood biomarker assay for Alzheimer's at the upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference.
Advertisement
The poster presentation, scheduled for Oct. 31 in Madrid, Spain, will showcase the company's progress in expanding the applicability of its innovative diagnostic tool.
Advertisement
The presentation, "Levels of age-related CD8 T cells binding HLA track with Alzheimer's disease status in HLA-A2+ and HLA-A2- patients: expansion of a flow cytometric blood biomarker assay to all patients," will be presented by Christopher Wheeler, Ph.D., CSO of T-Neuro Pharma.
Key Findings:
"We are excited to share these promising results with the scientific community at CTAD," says Wheeler. "Our findings suggest that we can potentially make the T-Track assay accessible to a much broader patient population, which could significantly impact early detection and monitoring of Alzheimer's."
T-Neuro Pharma invites conference attendees to visit their poster presentation to learn more about this research. The company will also schedule meetings during the conference to discuss potential collaborations and partnerships.
About T-Neuro PharmaT-Neuro Pharma is a biotechnology research company that develops early-stage diagnostics for Alzheimer's and other neurodegenerative diseases. The company targets early events in these devastating conditions, to allow sooner intervention that can improve the lives of patients and their families. For more information, please visit the company's website or contact [email protected] for media interviews.
View original content to download multimedia:https://www.prnewswire.com/news-releases/t-neuro-pharma-to-presents-expanded-alzheimers-disease-blood-biomarker-assay-at-clinical-trials-on-alzheimers-disease-ctad-conference-302288040.html
SOURCE T-Neuro Pharma
